[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337476-105":59,"doc-detail-337476-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antibody-mediated-targeting-of-claudins-in-cancer-review","Antibody-mediated targeting of Claudins in cancer - review","","Tight junction claudins are summarized as key regulators of carcinogenesis and metastasis, with altered claudin expression linked to tumor proliferation, metabolism, progression, and stemness. The review covers how claudins can serve as biomarkers for prognosis across solid cancers. It synthesizes pre-clinical advances enabling neutralizing antibodies and antibody-drug conjugates against Claudins-1, -3, -4, -6, and 18.2, then reviews clinical trials for Claudin-6 and Claudin-18.2. Emerging approaches, including CAR-T and BiTEs, are also discussed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antibody-mediated-targeting-of-claudins-in-cancer-review/337476/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antibody-mediated-targeting-of-claudins-in-cancer-review/337476.png","ImageObject",300,407,{"name":92,"@type":93},"Patrick","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What roles do claudins play in cancer according to the review?","Question",{"text":112,"@type":113},"Claudins regulate key steps in carcinogenesis and metastasis. Altered claudin expression patterns can influence tumor growth, metabolism, metastasis, and cell stemness.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which antibody-based strategies targeting claudins are discussed?",{"text":117,"@type":113},"The review summarizes neutralizing antibodies and antibody-drug conjugates targeting Claudins such as Claudins-1, -3, -4, -6, and 18.2.",{"name":119,"@type":110,"acceptedAnswer":120},"Are clinical trials covered, and for which claudins?",{"text":121,"@type":113},"Yes. The review summarizes clinical trials assessing the efficacy of antibodies targeting Claudin-6 and Claudin-18.2.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337476,1790168334,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","TYPE Review  \nPUBLISHED 02 February 2024 DOI 10.3389/fonc.2024.1320766  \nOPEN ACCESS  \nEDITED BY  \nAndrew Sanders,  \nUniversity of Gloucestershire, United Kingdom  \nREVIEWED BY  \nGeraldine Siegfried,  \nInstitut National de la Sante´ et de la Recherche Me´ dicale (INSERM),  \nFrance Jian Li,  \nMianyang Third People’s Hospital, China  \n*CORRESPONDENCE Peter M. Siegel  \n [peter.siegel@mcgill.ca](peter.siegel@mcgill.ca)  \nRECEIVED 12 October 2023  \nACCEPTED 09 January 2024  \nPUBLISHED 02 February 2024  \nCITATION  \nVonniessen B, Tabariès S and Siegel PM (2024) Antibody-mediated targeting of Claudins in cancer.  \nFront. Oncol. 14:1320766 .  \ndoi: 10.3389/fonc.2024.1320766  \nCOPYRIGHT  \n© 2024 Vonniessen, Tabariès and Siegel. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAntibody-mediated targeting of Claudins in cancer  \nBenjamin Vonniessen 1,2, S´ebastien Tabariès 1,2 and Peter M. Siegel 1,2,3,4,5*  \n1Goodman Cancer Institute, McGill University, Montre´al, QC, Canada, 2 Department of Medicine, McGill University, Montre´al, QC, Canada, 3 Department of Biochemistry, McGill University, Montre´al, QC, Canada, 4 Department of Anatomy & Cell Biology, McGill University, Montre´al, QC, Canada,  \n5 Department of Oncology, McGill University, Montre´al, QC, Canada  \nTight junctions (TJs) are large intercellular adhesion complexes that maintain cell polarity in normal epithelia and endothelia. Claudins are critical components of TJs, forming homo-and heteromeric interaction between adjacent cells, which have emerged as key functional modulators of carcinogenesis and metastasis. Numerous epithelial-derived cancers display altered claudin expression patterns, and these aberrantly expressed claudins have been shown to regulate cancer cell proliferation/growth, metabolism, metastasis and cell stemness. Certain claudins can now be used as biomarkers to predict patient prognosis in a variety of solid cancers. Our understanding of the distinct roles played by claudins during the cancer progression has progressed signiﬁcantly over the last decade and claudins are now being investigated as possible diagnostic markers and therapeutic targets. In this review, we will summarize recent progress in the use of antibody-based or related strategies for targeting claudins in cancer treatment. We ﬁrst describe pre-clinical studies that have facilitated the development of neutralizing antibodies and antibody-drug-conjugates targeting Claudins (Claudins-1, -3, -4, -6 and 18 . 2) . Next, we summarize clinical trials assessing the efﬁcacy of antibodies targeting Claudin-6 or Claudin-18 .2. Finally, emerging strategies for targeting Claudins, including Chimeric Antigen Receptor (CAR)-T cell therapy and Bi-speciﬁc T cell engagers (BiTEs), are also discussed.  \nKEYWORDS  \nClaudin, cancer progression, metastasis, antibody, antibody-drug conjugates, clinical trials  \nIntroduction  \nClaudins (CLDNs) are tetraspan transmembrane proteins that play key roles in the formation and maintenance of tight junctional complexes in epithelial and endothelial cells (1) . Since the discovery of CLDN1 and CLDN2 in 1998 (2), the protein family has expanded to include 26 members in humans, ranging in size from 21 to 34 kDa (1, 3, 4) . Claudins share a common structure comprised of the following: 1) a short N-terminal and longer C-terminal cytoplasmic region, 2) four transmembrane domains, 3) one intracellular  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \nloop and 4) two extracellular loops (ECL1, ECL2) (Figure 1) (5) . Claudins engage in homo-or hetero-typic interactions wit","cbCaiflEgQnErosn","https://ap.wps.com/l/cbCaiflEgQnErosn","pdf",2809993,16,"English","# Introduction\n## Claudins as tight junction components\n## Structural features of Claudins\n## Functional roles of ECL1 and ECL2\n## Tissue- and stage-dependent claudin expression","[{\"question\":\"What roles do claudins play in cancer according to the review?\",\"answer\":\"Claudins regulate key steps in carcinogenesis and metastasis. Altered claudin expression patterns can influence tumor growth, metabolism, metastasis, and cell stemness.\"},{\"question\":\"Which antibody-based strategies targeting claudins are discussed?\",\"answer\":\"The review summarizes neutralizing antibodies and antibody-drug conjugates targeting Claudins such as Claudins-1, -3, -4, -6, and 18.2.\"},{\"question\":\"Are clinical trials covered, and for which claudins?\",\"answer\":\"Yes. The review summarizes clinical trials assessing the efficacy of antibodies targeting Claudin-6 and Claudin-18.2.\"}]","Antibody-mediated targeting of Claudins in cancer - review | PDF",1790019275,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4511bd80f56efcf93ce19e4e16b3d17.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/214d2b5b15d9630ffee89449dbdc8cf9.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ecfb58e50c5c0f1efaa5f422f8360280.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ddc9ddcc9e858864c385a8a27ab03751.webp",980,1385]